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Cystic fibrosis (CF) is a genetic disease caused by mutations
in the cystic fibrosis transmembrane conductance regulator
(CFTR) gene and remains one of the most common fatal
hereditary disorders worldwide. Although CF is a complex
multiorgan disease, morbidity and mortality are mainly
determined by progressive chronic obstructive lung disease.
COPD is a major global health problem. The disease is
caused by both genetic and environmental factors; among
these, cigarette smoking (CS) is the main risk factor and is
associated with a marked oxidative stress burden and a
persistent airway inflammatory response.
Although the etiology and the pathophysiology of these
diseases are different, they share key phenotypical features,
including reduced mucociliary clearance, airway mucus
obstruction especially in small airways, chronic neutrophilic
airway inflammation, and chronic/recurrent bacterial infec-
tions. In both diseases, a persistent high-intensity inflamma-
tion, driven by continuous neutrophil recruitment, leads to
permanent structural damage of the airways and progressive
airflow obstruction.
Several defective inflammatory/immune responses have
been linked to CFTR deficiency including innate and
acquired immunity dysregulation, cell membrane lipid
abnormalities, and various transcription factor-signaling
defects. During the past few years, several in vitro and
in vivo studies have shown that CS decreases CFTR expres-
sion and function and induces an acquired CFTR
dysfunction in patients with a normal CFTR genotype. Thus,
it is possible that commonmechanismsmay contribute to the
chronic nonresolving inflammation and the altered immune
responses in both CF and COPD. These mechanisms how-
ever are still poorly defined.
This special issue aims to contribute to knowledge of
these mechanisms and to provide a better understanding of
altered inflammatory/immune responses in both CF and
COPD as well as a roadmap for potential novel therapeutic
approaches relevant to both diseases. We hope this issue
may be a useful reference to all readers and investigators
interested in potential mechanistic links and common
therapeutic targets in CF and COPD and that it may be an
incentive for further investigations in this field.
Airway epithelial cells are among the first sites of contact
for pathogens and other noxious environmental irritants and
play a critical role in maintaining normal airway functions as
well as in modulating inflammatory/immune responses in
the airways. Relevant molecular and morphologic changes
occur in the airway epithelium in both CF and COPD. In
their review, V. De Rose et al. addressed the evidence for a
critical role of dysfunctional airway epithelium in impaired
local defences, altered immune responses, chronic airway
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inflammation, and remodelling in CF and COPD, highlight-
ing the common mechanisms involved in epithelial dysfunc-
tion as well as the similarities and differences in the two
diseases. They discuss the in vitro and in vivo findings show-
ing that CS induces an acquired CFTR dysfunction in
patients with COPD, reducing the expression and/or func-
tion of the protein; they highlight that this CFTR dysfunction
is involved in most of the pathogenetic pathways common to
both COPD and CF and may represent a potential target for
the development of novel therapeutic approaches in COPD.
M. Stolarczyk and B. J. Scholte reviewed the role of the
EGFR/ADAM17 axis in the development of chronic lung dis-
ease in CF and COPD. They discuss the evidence suggesting
that the ADAM17/EGFR axis and downstream regulatory
pathways are hyperactive in both diseases. The enhanced
ADAM17/EGFR signaling may contribute to inflammation,
epithelial metaplasia, and fibroblast and smooth muscle
activation, as well as tissue remodelling observed in CF and
COPD lung disease. They also discuss a possible mechanistic
link between EGFR/ADAM17 activity, CF, and COPD,
suggesting that the genetic CFTR defect in CF and the CS-
induced CFTR dysfunction in COPD interfere with glutathi-
one transport in the airways, enhancing oxidative stress,
which would activate the ADAM17/EGFR axis.
In the context of airway inflammation and mucosal
immunity, M. Puccetti et al. have reviewed the role of the aryl
hydrocarbon receptor (AhR) in COPD and CF lung disease.
They discuss the effects of this receptor on the immunologi-
cal status of the gastrointestinal and respiratory tracts and
highlight its relevance in establishing andmaintaining signal-
ing networks which facilitate host/microbe homeostasis at
the mucosal interface. They also analyze the evidence
suggesting that changes in AhR expression and function
may be a risk factor for COPD and other lung inflammatory
diseases in smokers and that the AhR status could be dysreg-
ulated in smokers. Finally, they also discuss the possible
therapeutic use of AhR ligands in cystic fibrosis.
A common feature shared by CF and COPD is the
increased susceptibility to respiratory infections; recurrent
infectious exacerbations significantly contribute to morbidity
and mortality in both diseases. To better understand the
mechanisms of recurrent exacerbations in COPD, G. Pehote
et al. investigated the mechanisms of CS-induced impair-
ment of bacterial phagocytosis in this disease and showed
that an autophagy defect mediated by CS is a critical mecha-
nism involved in the impairment of phagocytosis that may
account for recurrent exacerbations in COPD. An autophagy
defect has also been described in CF and suggested to
underlie the increased susceptibility to infections with certain
microbes in this disease; thus, the study of G. Pehote et al.
suggests additional common mechanisms responsible for
the increased susceptibility to respiratory infections in
COPD and CF. The findings of this study also suggest
the therapeutic potential of autophagy-inducing drugs,
with antioxidant characteristics, in restoring CS-impaired
phagocytosis in COPD and other chronic airway inflam-
matory diseases, such as CF.
A genuine microbiota resides in the lung, which ema-
nates from colonization by the oropharyngeal microbiota.
Changes in the oropharyngeal microbiota might be the
source of dysbiosis observed in the lower airways in patients
suffering from chronic airway inflammatory diseases, includ-
ing COPD, asthma, and CF. S. Boutin et al. analyzed whether
differences occur in the throat microbiota of children with
asthma and CF in comparison to that of healthy children
and reported that the microbiota in these three populations
shows high levels of similarities, revealing the existence of a
core microbiome. However, in the CF group, a decrease in
both diversity and total bacterial load in the throat microbi-
ota was observed in comparison to asthmatic and control
children, whereas, on the contrary, a significant increase
was found in typical pathogens like Pseudomonas and
Staphylococcus and the atypical pathogen Phyllobacterium,
which is consistent with the impaired host defences associ-
ated with CFTR dysfunction in the CF airways.
Toll-like receptors (TLRs) expressed on the airway
epithelium respond to infection or tissue damage by sensing
local microbial and host-derived factors; TLRs recognize LPS
which activates intracellular molecules such as IL-1 receptor-
associated kinases (IRAKs) leading to overproduction of pro-
inflammatory cytokines. IRAK-M, a negative regulator of
TLR-mediated NFkB activation, is expressed in both airway
epithelial cells and monocytes/macrophages in healthy lungs.
H. Gong et al., using IRAK-M KOmice, studied the effects of
IRAK-M deficiency on CS-induced airway inflammation
under acute or subacute conditions. They showed that
IRAK-M has distinctive effects on airway inflammation and
influences the Treg/Th17 balance and expression of costimu-
latory molecules by dendritic cells and macrophages,
depending on the duration and intensity of the stimulus. In
fact, whereas upon short-term CS exposure IRAK-M pro-
vided airway protection, it played a proinflammatory role
in airway pathology upon subacute CS exposure. As TLRs
largely contribute to chronic airway inflammation also in
CF lung disease, it would be interesting in the future to inves-
tigate the effect of IRAK-M on CF airway inflammation.
Increasing evidence support a crucial role of long non-
coding RNAs (lncRNAs) in controlling gene expression; fur-
thermore, it has been shown that lncRNAs play important
roles in biological and pathological processes and are dysreg-
ulated in various human diseases, including CF and COPD.
X. Qu et al. evaluated lncRNAs and mRNA expression
profiles of peripheral blood mononuclear cells (PBMCs)
from healthy nonsmokers, smokers without airflow limita-
tion, and COPD patients to determine if lncRNA differen-
tial expression may be linked to dysregulated mRNA
expression relevant to COPD pathogenesis. They identified
158 differentially expressed lncRNAs in PBMCs from
COPD patients compared with smokers without airflow
limitation; they further analyzed the regulation network
between lncRNAs and mRNAs, where the genes CXCL16,
HMOX1, SLA2, and SIGLEC14 were predicted to be regu-
lated by certain lncRNAs. Their study may provide clues
for further studies targeting lncRNAs to control inflamma-
tion in COPD.
In summary, the articles presented in the present spe-
cial issue constitute a contribution to the idea that COPD
and CF share some clinical and pathophysiological aspects
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and that progress in the understanding of rare diseases
(e.g., cystic fibrosis) could contribute to the development
of novel approaches for more common diseases (e.g.,
COPD and bronchiectasis).
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